Boy, on Friday it will have been 2 weeks since they completed dosing in the third and final cohort of the Phase 1 trial. I get this feeling that there are a lot of eyes watching to see these results announced. Based on BDD's expertise and the safety profile of B, I believe we will see some great results. Would definitely not want to be short on this stock right now. Hopefully we can get a nice PR before the 10Q. The double whammy would be an offer sheet or deal announcement for B-OM. GLTA!!